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a b s t r a c t
A case of Mucha-Habermann disease (MHD), possibly associated with macrophage activa-
tion syndrome (MAS), is reported. The purpose of this paper was to describe the rare MHD 
(also known as pityriasis lichenoides et varioliformis acuta – PLEVA) in a 28-year-old male, 
who presented with generalized ulceronecrotic lesions on the skin and mucosae, gastroin-
testinal involvement, and heart andliver failure, associated with continuous high fever. The 
patient might have progressed to MAS and eventually died. The MHD is rare, potentially 
fatal and has severe systemic complications. The importance of early diagnosis and aggres-
sive treatment is emphasized.





Síndrome de ativação macrofágica
r e s u m o
Os autores descrevem um caso de doença de Mucha-Habermann (DMH), que cursou com 
quadro sugestivo de síndrome de ativação macrofágica (SAM). O objetivo do trabalho foi 
descrever um caso de rara vasculite de Mucha-Habermann (pitiríase liquenoide e vario-
liforme aguda – PLEVA) em paciente de 28 anos que apresentou lesões ulceronecróticas 
generalizadas em pele e mucosas, acometimento gastrointestinal, cardíaco e hepático, as-
sociados a febre alta contínua, com provável evolução para SAM e posterior óbito. Trata-se 
de doença rara, potencialmente fatal, com graves complicações sistêmicas. Os autores res-
saltam a importância de seu diagnóstico e de tratamento agressivo.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Mucha-Habermann disease (MHD) was described by Degos 
et al. in 1966.1 It is considered a severe variant of pityria-
sis lichenoides et varioliformis acuta (PLEVA), characterized 
by polymorphic, ulceronecrotic and crusted lesions on the 
skin and mucosae, associated with high fever and system-
ic manifestations. So far, only 40 cases of MHD have been 
reported, and no treatment is available for that potentially 
lethal condition.2 We report the case of a male patient with 
MHD associated with probable macrophagic activation syn-
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drome (MAS), and highlight the relevance of recognizing this 
syndrome. 
Case report
The patient is a 28-year-old male, previously healthy, admitted 
to the Hospital Universitário Clementino Fraga Filho, of the Uni-
versidade Federal do Rio de Janeiro, due to cutaneous fi ndings 
initiated after the use of amoxicillin to treat a dental abscess. 
The patient had ulceronecrotic and crusted cutaneous-muco-
sal lesions on the limbs and trunk, associated with continuous 
high fever, emaciation, diarrhea, diffuse facial edema (Fig. 1), 
and huge hepatomegaly. The patient underwent comprehen-
sive examination during hospitalization, the diagnosis of fever 
of obscure originbeing established. After improvement with 
symptomatic drugs, antibiotics and prednisone (1 mg/kg/day), 
he was followed up on an outpatient basis. 
After 15 days, the patient was readmitted with congestive 
heart failure, whose cause was viral myocarditis. The fever 
peaks persisted. He showed only residual hypochromic cu-
taneous lesions. After cardiac compensation and antibiotic 
therapy (associated pneumonia), clinical improvement was 
observed. 
Thirty days later, the patient was readmitted again with 
ulceronecrotic skin lesions (Fig. 2), high fever, jaundice, nau-
sea and prostration. Viral and bacterial serologies, cultures, 
coagulogram and imaging tests resulted unspecifi c. The skin 
biopsy showed a lichenoid pattern, necrosis of keratinocytes 
and typical alterations of pityriasis lichenoides acuta. 
Those data in association with high fever and systemic 
manifestations confi rmed the diagnostic hypothesis of MHD. 
The patient developed liver failure, hyperferritinemia, and 
bicytopenia (white and megakaryocytic series). His general 
health status worsened, and he progressed to apathy and 
coma, being transferred to the intensive care unit with the 
hypothesis of MAS. Clinical support was instituted along with 
antibiotic therapy and methylprednisolone pulse therapy 
(500  mg) for three consecutive days. Myelogram and bone 
marrow biopsy evidenced no hemophagocytosis on the occa-
sion. Although the skin lesions and fever improved, the pa-
tient developed acute pancreatitis, pulmonary sepsis, renal 
failure and refractory shock, progressing to multiple organ 
dysfunction and death after 45 days of hospitalization.
Discussion
Mucha3 and Habermann4 described in 1916 and in 1925, re-
spectively, a form of pityriasis lichenoides characterized by 
the sudden onset of papulo-vesicular eruptions, called ‘pity-
riasis lichenoides et varioliformis acuta’ (PLEVA). 
In 1966, Degos et al.1 described the MHD in areportof two 
cases with severe fi ndings titled “Parapsoriasis ulceronecrotique 
hyperthermique”.2,5 It is considered a severe variant of PLEVA, 
with polymorphic, ulceronecrotic and crusted lesions on the 
skin and mucosae, associated with high fever and systemic 
manifestations.2,6,7 Its etiology remains controversial and un-
known, but it is believed to be related to infectious agents or 
immune complex deposition. The infectious agents most likely 
involved are as follows: adenovirus; Epstein-Barr virus; Toxo-
plasma gondii; Parvovirus B19; Staphylococcus aureus; Streptococcus 
pyogenes; and Pseudomonas aeruginosa.7 A mechanism related to 
clonal lymphoproliferative disorder has also been proposed.8-11 
Male patients predominate, the MHD incidence being higher 
among children, adolescents and young adults. The mean age 
observed was 27 years, ranging from 4 to 82 years.12
The cutaneous manifestations of PLEVA usually precede 
the acute and severe course of disease.12-14 The lesions are 
characteristically polymorphic, ulceronecrotic, crusted and 
widespread, frequently secondarily infected, and tend to 
resolve with a hypochromic scar. The oral, genital and con-
junctival mucosae might also be affected.11 The systemic 
manifestations described include liver and gastrointestinal 
dysfunction, lymphadenopathy, pancytopenia, cardiopathy, 
disseminated intravascular coagulation, interstitial pneumo-
nitis, central nervous system impairment and rheumatologic 
manifestations,13 similarly to those of our patient.
Fig. 1 – Patient on his fi rst admission, showing diffuse 
facial edema and ulceronecrotic lesions on the skin and 
mucosae.
Fig. 2 – Ulceronecrotic lesions on the patient’s trunk (the 
whitish aspect is due to the use of water paste).
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The diagnosis is based on the presence of high fever, char-
acteristic clinical fi ndings, typical cutaneous changes, and 
skin biopsy compatible with PLEVA (perivascular lymphocytic 
infl ammatory infi ltrates in the superfi cial dermis, with epi-
derma lexocytosis of lymphocytic debris and parakeratotic 
scales, with accumulation of infl ammatory cells between the 
different layers).11,14 The following are commonly observed 
during disease course: leukocytosis; C-reactive protein (CRP) 
elevation; increased erythrocyte sedimentation rate (ESR); 
hypergammaglobulinemia; and hypoproteinemia.13 Our pa-
tient’s major laboratory fi ndings were as follows: pancytope-
nia; increased CRP and ESR; hypoalbuminemia; and ferritin 
over 1,430 ng/dL (reference range: 5–148 ng/dL).
The prognosis is worse in adults, with mortality rate of 
33% – there is no report of death in children.11 Death usually 
results from pneumonia, sepsis, pulmonary thromboembo-
lism, heart failure, hypovolemic shock, and massive thrombo-
sis of the superior mesenteric artery.8,11
Although several therapeutic modalities have been report-
ed, so far there is no defi nitive treatment recommended for 
all patients.11 Most are treated with multiple therapeutic op-
tions, such as systemic glucocorticoids, antibiotics, acyclovir, 
methotrexate, phototherapy, immunoglobulin, cyclosporine13 
and dapsone, refl ecting the complexity of the management of 
those patients.
More recent studies have reported success with the use 
of methotrexate associated with methylprednisolone pulse 
therapy.13 Therapy effectiveness is diffi cult to measure, be-
cause the number of cases reported is small.11,13 Critical care, 
supportive therapy and management of superinfections are 
usually required due to the severity of the pathology. Anti-
tumor necrosis factor-α (TNF-α) agents may be fi rst-line ther-
apy in the future, since high TNF-α titers have been observed 
in those patients. However, further studies are necessary to 
clarify that observation.13
We reported a case initially diagnosed as fever of obscure 
origin despite extensive investigation. The association of per-
sistent high fever, disseminated ulceronecrotic cutaneous le-
sions, and typical histopathological fi ndings in the skin biop-
sy corroborated the diagnosis of MHD. The patient, however, 
progressed with alterations typical of MAS, such as hyperfer-
ritinemia, fever, bicytopenia, apathy, liver and blood dysfunc-
tions. Although there was no evidence of hemophagocytosis 
in the bone marrow biopsy, that diagnostic hypothesis was 
not ruled out, because, in the disease’s initial phase, bone 
marrow fi ndings can be unspecifi c.14-17 The patient had sev-
eral complications, such as pulmonary sepsis, acute pancre-
atitis, liver and renal failures, progressing to death, despite 
broad spectrum antibiotic therapy, methylprednisolone pulse 
therapy and supportive therapy at the intensive care unit.17,18
We found no association between MHD and MAS report-
ed in the literature. It is worth noting the similarity of the 
triggers of both pathologies, which may be correlated in the 
future.
Conclusion
Although rare, the potentially fatal MHD should be considered 
when assessing patients with high fever, ulceronecrotic skin 
lesions and systemic manifestations. Skin biopsy is valuable 
in such cases. The MHD’s rarity and diffi cult management re-
inforce the importance of exchanging experience about those 
patients.
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